Gan & Lee Pharmaceuticals. (SHA:603087)
China
· Delayed Price · Currency is CNY 59.81
-0.42 (-0.70%)
Apr 29, 2026, 3:00 PM CST
SHA:603087 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 35,849 | 40,515 | 26,332 | 31,066 | 18,429 | 39,499 | Upgrade
|
| Market Cap Growth | 33.24% | 53.87% | -15.24% | 68.57% | -53.34% | -46.80% | Upgrade
|
| Enterprise Value | 32,445 | 37,352 | 21,268 | 26,918 | 13,463 | 34,935 | Upgrade
|
| Last Close Price | 60.23 | 68.07 | 43.35 | 50.98 | 31.55 | 67.67 | Upgrade
|
| PE Ratio | 34.77 | 35.43 | 42.84 | 91.35 | - | 27.19 | Upgrade
|
| Forward PE | 23.34 | 11.40 | 11.40 | 11.40 | 11.40 | 25.81 | Upgrade
|
| PS Ratio | 9.09 | 10.00 | 8.65 | 11.91 | 10.76 | 10.94 | Upgrade
|
| PB Ratio | 3.03 | 3.48 | 2.38 | 2.89 | 1.92 | 3.89 | Upgrade
|
| P/TBV Ratio | 3.17 | 3.57 | 2.44 | 2.97 | 1.98 | 4.00 | Upgrade
|
| P/FCF Ratio | - | - | 272.84 | - | - | 102.30 | Upgrade
|
| P/OCF Ratio | 44.97 | 51.66 | 49.01 | 283.83 | 62.12 | 36.64 | Upgrade
|
| EV/Sales Ratio | 8.22 | 9.22 | 6.98 | 10.32 | 7.86 | 9.67 | Upgrade
|
| EV/EBITDA Ratio | 29.94 | 34.09 | 38.98 | 67.16 | - | 22.24 | Upgrade
|
| EV/EBIT Ratio | 42.69 | 47.06 | 72.20 | 149.52 | - | 25.13 | Upgrade
|
| EV/FCF Ratio | -115.82 | - | 220.38 | - | - | 90.48 | Upgrade
|
| Debt / Equity Ratio | 0.00 | 0.00 | 0 | 0.00 | 0.00 | 0.00 | Upgrade
|
| Debt / EBITDA Ratio | 0.01 | 0.01 | 0.01 | 0.02 | - | 0.01 | Upgrade
|
| Debt / FCF Ratio | - | - | 0.05 | - | - | 0.05 | Upgrade
|
| Net Debt / Equity Ratio | -0.29 | -0.30 | -0.22 | -0.45 | -0.49 | -0.51 | Upgrade
|
| Net Debt / EBITDA Ratio | -3.17 | -3.17 | -4.40 | -12.09 | 9.82 | -3.30 | Upgrade
|
| Net Debt / FCF Ratio | 12.16 | 24.52 | -24.85 | 10.92 | 6.86 | -13.44 | Upgrade
|
| Asset Turnover | 0.32 | 0.33 | 0.26 | 0.23 | 0.16 | 0.36 | Upgrade
|
| Inventory Turnover | 0.88 | 0.95 | 0.81 | 0.96 | 0.68 | 0.70 | Upgrade
|
| Quick Ratio | 5.72 | 5.02 | 3.31 | 6.77 | 6.05 | 12.65 | Upgrade
|
| Current Ratio | 7.99 | 6.72 | 4.73 | 7.99 | 6.97 | 14.15 | Upgrade
|
| Return on Equity (ROE) | 8.85% | 10.08% | 5.64% | 3.35% | -4.45% | 15.21% | Upgrade
|
| Return on Assets (ROA) | 3.81% | 4.02% | 1.55% | 1.01% | -3.94% | 8.54% | Upgrade
|
| Return on Invested Capital (ROIC) | 8.68% | 8.78% | 3.95% | 3.34% | -13.72% | 25.40% | Upgrade
|
| Return on Capital Employed (ROCE) | 6.30% | 6.70% | 2.60% | 1.60% | -6.90% | 13.40% | Upgrade
|
| Earnings Yield | 2.86% | 2.82% | 2.33% | 1.09% | -2.38% | 3.68% | Upgrade
|
| FCF Yield | -0.78% | -0.35% | 0.37% | -1.43% | -3.73% | 0.98% | Upgrade
|
| Dividend Yield | 2.49% | - | 3.46% | 0.39% | - | 0.44% | Upgrade
|
| Payout Ratio | 57.73% | 52.25% | 68.42% | - | - | 15.46% | Upgrade
|
| Buyback Yield / Dilution | -0.52% | -0.26% | -4.28% | -0.58% | -0.46% | -5.28% | Upgrade
|
| Total Shareholder Return | 1.98% | -0.26% | -0.82% | -0.19% | -0.46% | -4.84% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.